GlycoEra AG, a biotechnology company based on the Tuwag-Areal in Wädenswil, today announced the completion of an oversubscribed Series B financing in the amount of 130 million US dollars.
We are delighted and congratulate them warmly!
GlycoEra is pioneering the development of first-in-class products for the extracellular degradation of circulating proteins for the treatment of autoimmune diseases. The company is advancing a number of products into human clinical trials.
Dominique N. Sirena, PhD, co-founder and CMfO of GlycoEra, is grateful for the recognition of their work: «Thanks to the support of our investors, we are able to bring our product candidate GE8820 into the clinical phase and validate the promising preclinical data clinically. The degradation of IgG4 with our protein degradation product enables new therapeutic approaches for patients with autoimmune diseases due to its specific, rapid and profound effect.»
Find out more here.
The picture shows Dominique N. Sirena at his workplace in Wädenswil.